Four months in, a man has been on three different doses of the same medication. Up once, down once, back up. Each time he goes in, something changes. Each time, he drives home wondering whether the person prescribing this actually knows what they’re doing.
He’s started calling himself a guinea pig when he tells his brother about it.
I understand why it feels that way. But the adjusting isn’t guesswork covering for uncertainty. It’s the method. Nobody in the world can look at you and know your correct dose in advance, and any prescriber who acts like they can is worth being suspicious of.
There’s no way to know your dose before you take it
Two people the same height and weight, with similar symptoms, can need very different amounts of the same medication.
Some of that comes down to liver enzymes. Genetic differences in how quickly you break a drug down mean the same pill can leave one person with twice the blood level of another. Some of it is age, other medications you take, how your kidneys and liver are working, and what else is going on medically.
None of that shows up on a first visit. It shows up in how you respond, which is why the response is what gets measured.
Why they start you low
Starting at a low dose isn’t caution for its own sake. Side effects tend to hit hardest at the beginning and when a dose goes up, and starting low gives your system time to settle before the dose climbs.
It also protects the trial. Someone who starts at a full dose and feels awful in week one usually stops, and then nobody learns anything about whether that medication would have worked.
The dropout numbers are worse than most people expect. A study in the American Journal of Psychiatry (2006) following 829 adults who started antidepressant treatment found that 42.4% stopped within the first 30 days, and only 27.6% were still taking it after 90 days. Most people who quit do it before the medication has been given a fair chance at a fair dose.
Why higher isn’t automatically better
The instinct when something isn’t working is to want more of it. Sometimes that’s right. Often it isn’t.
A dose-response meta-analysis in Lancet Psychiatry (2019) pooled 77 randomized trials covering 19,364 people. For SSRIs, benefit increased as the dose rose into the lower-to-middle part of the licensed range, then flattened out. Pushing past that point didn’t add much benefit, while side effects and dropouts from side effects kept climbing.
So a prescriber who declines to raise your dose isn’t being stingy. Above a certain point you’re mostly buying side effects.
And sometimes the adjustment goes down. If you’re getting benefit but can’t tolerate the nausea or the flat feeling, lowering the dose can be what makes the medication something you’ll actually keep taking.
The check-ins are the treatment
The STAR*D trial, the largest real-world antidepressant study run in the U.S. and funded by NIMH, used something called measurement-based care. Patients were scored on standard scales at set points, and if they hadn’t reached remission by weeks 4, 6, or 9 and were tolerating the medication, the protocol called for the dose to go up.
Average time to remission in that study was around 47 days.
That’s what your appointments are. Each visit is a decision point: is this dose doing enough, is it doing too much, has enough time passed to judge. A prescriber who never adjusts anything isn’t being steady. They’re not measuring.
Which is also why what you report matters more than you think. “A bit better, I guess” is hard to act on. Specifics help: how many nights you slept through, whether you got to work on time, whether the side effect that bothered you in week two is still there.
Alcohol changes the math
If you’re drinking while your dose is being worked out, the picture gets muddy, and the person adjusting your medication is making decisions based on incomplete information.
Alcohol disrupts deep sleep, which pushes mood and anxiety in the wrong direction. It also interacts with a long list of medications. NIAAA-funded research analyzing data from more than 26,000 U.S. adults found that roughly 42% of adults who drink also take medications known to interact with alcohol. Among drinkers over 65, it was close to 78%.
None of this means you’ll be judged for saying so. It means a dose gets raised chasing a problem that isn’t about the dose at all. Tell your prescriber what you’re actually drinking, including the nights you’d rather not mention.
When and how to raise it
Say something at your next appointment if you’ve been at the same dose for eight weeks with no change, if side effects are interfering with work or sleep, or if you feel steadier but not well.
Call sooner if you feel worse after a change, if your drinking has increased since starting, or if you’re having thoughts of not wanting to be here. Don’t change or stop a dose on your own; some medications need to be tapered.
Not everyone has a prescriber who follows up properly. If yours hasn’t seen you in months, ask your primary care doctor for a referral, call the behavioral health number on your insurance card, or contact a practice offering psychiatry and medication management services and ask what their follow-up schedule looks like.
If you’re having thoughts of hurting yourself, call or text 988 in the U.S. It’s free and available around the clock.
One more thing from that 2006 study: people who were also receiving psychotherapy were far more likely to still be on their medication past the first month, 68% compared with 44%. Whatever is going on in your dose adjustments, you’re more likely to make it through them with someone else in the room.
Sources
- Olfson M, Marcus SC, Tedeschi M, Wan GJ (2006). Continuity of Antidepressant Treatment for Adults With Depression in the United States. American Journal of Psychiatry, 163(1), 101–108 — https://pubmed.ncbi.nlm.nih.gov/16390896/
- Furukawa TA, Cipriani A, Cowen PJ, Leucht S, Egger M, Salanti G (2019). Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry, 6(7), 601–609 — https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(19)30217-2/fulltext
- Trivedi MH, Rush AJ, Wisniewski SR, et al. (2006). Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STARD: Implications for Clinical Practice.* American Journal of Psychiatry, 163(1), 28–40 — https://psychiatryonline.org/doi/full/10.1176/appi.ajp.163.1.28
- National Institute on Alcohol Abuse and Alcoholism (NIAAA), NIH study reveals many Americans at risk for alcohol-medication interactions — https://www.niaaa.nih.gov/news-events/news-releases/nih-study-reveals-many-americans-risk-alcohol-medication-interactions
